Yaohua Pharmaceutical has entered the Australian Eye Research Center in Melbourne and officially launched its Australian market layout.

Yaohua Pharmaceutical (6446), a new drug research and development company, announced today (23rd) that its Australian subsidiary will enter the Center for Eye Research Australia (CERA) in Melbourne on October 1 to establish an Australian operation base. It has immediately started preparations for the Australian drug license application for its new drug Ropeg for the dual indications of polycythemia vera (PV) and essential thrombocythemia (ET), officially launching its Australian market layout.

The board of directors of Yaohua Pharmaceutical decided to establish an Australian subsidiary in 2018. This year, it will further launch local base and team building according to the plan, and recruit senior operating executives to join, gradually establishing local clinical development and regulatory capabilities. Yaohua Pharmaceutical stated that CERA is Australia's internationally leading independent medical research institution. It maintains close cooperation with the University of Melbourne and the Royal Victoria Eye and Ear Hospital, and actively establishes cooperative relationships with international biotech pharmaceuticals, academic research and medical institutions. After Yaohua Pharmaceutical enters CERA, it is expected to accelerate its integration into Melbourne's biomedical research and development ecosystem, expand local clinical research and industrial networks, and lay the foundation for the Australian market layout.

Yaohua Pharmaceutical stated that the company has adopted a global direct sales strategy for many years and has successively established subsidiaries and local teams in the United States, Japan, South Korea, China, Singapore and other markets to promote clinical development, drug license applications and product commercialization locally. This year, it completed the acquisition of Canadian partner FORUS Therapeutics to further strengthen its North American market layout. As Ropeg continues to expand new indications, the company is simultaneously expanding its global R&D, clinical, regulatory and commercialization capabilities. The launch of the Australian base is the latest step in the strategy.

Yaohua Pharmaceutical pointed out that the establishment of its Australian operating base is an important step in the company's expansion of its Asia-Pacific presence. In the future, we will make good use of Australia's advantages in clinical trials and biomedical R&D, deepen cooperation with local medical, academic research and industrial partners, connect Asia-Pacific and global R&D resources, and accelerate the development and commercialization of new drugs.